Telix Announces Executive Leadership Appointments
Telix today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
Telix today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an important development in radioisotope production.
First Patient Dosed in Phase II ‘IPAX-Linz’ Study of TLX101 for Glioblastoma Therapy
Telix today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM).
Presentation to Jefferies London Healthcare Conference
Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies London Healthcare Conference in London on Thursday 17 November 2022.
Telix Acquires Optimal Tracers
Telix today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials.
Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of studies evaluating CAIX expression in cancers other than clear cell renal cell carcinoma (ccRCC), supporting Telix’s goal to rapidly expand the CAIX program into other indications beyond kidney cancer.
EANM 2022 wrap-up : Shifting perspectives in genitourinary oncology through nuclear medicine
At our recent EANM 2022 symposium, Telix brought together some of the world’s key opinion leaders to discuss the impact that nuclear medicine is having on their field. It was an exciting and informative afternoon filled with fascinating insights. If you missed the event, you can find interesting aspects from each of our expert speakers below. Prepare to shift your perspectives!
Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022
Telix is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, held today at the AusBiotech 2022 national conference in Perth.
Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide
Telix today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland (UQ), to develop a radiolabelled molecule targeting an immune checkpoint protein. The announcement was made at the AusBiotech 2022 national conference, currently being held in Perth, Western Australia.
Telix Reports Third Quarter 2022 Financial Results
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022.